<unk> , sold under the brand name Sirturo, is a medication used to treat active tuberculosis. Specifically, it is used to treat multi-drug-resistant tuberculosis (MDR-TB) along with other medications for tuberculosis. It is used by mouth. Common side effects include nausea, joint pains, headaches, and chest pain. Serious side effects include QT prolongation, liver dysfunction, and an increased risk of death. While harm during pregnancy has not been found, it has not been well studied in this population. It is in the diarylquinoline antimycobacterial class of medications. It works by blocking the ability of M. tuberculosis to make adenosine 5'-triphosphate (ATP).<unk>  was approved for medical use in the United States in 2012. It is on the World Health Organization's List of Essential Medicines. The cost for six months is approximately US$900 in low-income countries, US$3,000 in middle-income countries, and US$30,000 in high-income countries. The public sector invested US$455–747 million in developing<unk> . This is thought to be 1.6× to 5.1× what the owner, Janssen Biotech, invested (estimated at US$90-240 million). If capitalized and risk-adjusted, these costs become US$647-1,201 million and US$292-772 million, respectively.
Bedaquiline
Selegiline
Rasagiline
Perhexiline
Tetrabenazine
Deutetrabenazine
Butriptyline
3-Quinuclidinyl benzilate